Los puntos clave no están disponibles para este artículo en este momento.
Durvalumab therapy resulted in significantly longer overall survival than placebo. No new safety signals were identified. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).
Antonia et al. (Tue,) studied this question.